Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1572MR)

This product GTTS-WQ1572MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1572MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13418MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ3090MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ1414MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ7861MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ13219MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ5391MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ3017MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ6107MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA COR-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW